Cervical Cancer Screening: Pap vs HPV Test and Intervals

Key points#

• Cervical cancer screening looks for high-risk HPV and the cervical-cell changes it can cause, allowing most important abnormalities to be evaluated before cancer develops.
• For average-risk people aged 21 to 29, ACOG recommends cervical cytology (a Pap test) every 3 years.
• For ages 30 to 65, clinician-collected primary high-risk HPV testing every 5 years is preferred. Co-testing every 5 years is an acceptable alternative; cytology alone every 3 years is a fallback when HPV-based testing is unavailable or is chosen after counseling.
• Patient-collected primary HPV screening is a qualified option for average-risk patients aged 30 to 65 who prefer it. ACOG recommends a 3-year interval, an FDA-approved or cleared kit used within its labeling, clinician involvement, and established notification, documentation, and follow-up systems.
• Self-collection produces a vaginal sample for HPV testing, not a Pap test. A positive result may require clinician-collected cervical cytology, genotyping, colposcopy, biopsy, or another follow-up step.
• An abnormal or HPV-positive result usually does not mean cancer. Screening before 21, after an eligible exit at 65, or after qualifying cervix-removing hysterectomy is generally not recommended; high-risk histories require a different plan.

Cervical cancer screening looks for high-risk human papillomavirus (hrHPV) and the cervical-cell changes that persistent infection can cause. The 2026 ACOG-endorsed HRSA-WPSI framework puts primary hrHPV testing first for average-risk patients aged 30 to 65 while preserving co-testing and cytology alternatives. It also adds patient self-collection as a qualified option, with a different interval and specific safeguards.

That works because cervical cancer is one of the few cancers we can usually prevent rather than merely catch early. The tests, the timing, and the follow-up steps can feel like an arbitrary set of rules, but each piece follows from a single fact: cervical cancer almost always develops slowly, through a chain of events we can interrupt. Once that biology is clear, the schedule stops looking like bureaucracy and starts looking like a plan.

What cervical cancer screening is actually looking for#

It helps to be precise about the goal. Screening is not mainly trying to find cancer. It is trying to find the changes that come before cancer, while they are still easy to treat.

Nearly all cervical cancer is driven by persistent infection with a high-risk type of human papillomavirus (HPV). Over years, a lingering high-risk infection can push cervical cells through a series of precancerous changes, sometimes called dysplasia or cervical intraepithelial neoplasia (CIN). Screening aims to catch those changes, or the virus driving them, well before any of it becomes cancer.

Two different tools do this. The Pap test, or cervical cytology, collects a sample of cells from the surface of the cervix and looks at them under the microscope for abnormal shapes and features. The HPV test uses a similar sample but checks for the genetic material of the high-risk virus types themselves. One asks have the cells started to change? The other asks is the virus that causes those changes present?

This is also why a positive HPV result is not a diagnosis of cancer, or even of precancer. It is a risk signal. High-risk HPV is common, most infections clear on their own, and only a small fraction that persist go on to cause the cell changes we care about. The cervix is slow-changing tissue, and that slowness is what makes screening work: there is a long window in which a simple treatment can prevent cancer entirely.

Pap, primary HPV, co-testing, and self-collection#

The available strategies share one prevention goal, but the current framework does rank them for average-risk people aged 30 to 65.

• Clinician-collected primary hrHPV testing, preferred: a clinician collects a cervical specimen and the laboratory first tests for high-risk HPV. The routine interval after a negative screen is 5 years.
• Co-testing, acceptable: the same clinician-collected cervical specimen is tested for both hrHPV and abnormal cells. The routine interval is 5 years when primary HPV testing is unavailable or the patient chooses co-testing after counseling.
• Cytology alone, a fallback: a clinician collects cervical cells for microscopic examination. The routine interval is 3 years when primary HPV testing and co-testing are unavailable or the patient chooses cytology after counseling.
• Patient-collected primary hrHPV testing, a qualified option: the patient collects a vaginal specimen using an FDA-approved or cleared kit within its labeling. ACOG recommends a 3-year interval, not 5 years, because current evidence does not yet support a 5-year cadence for patient-collected specimens.

HPV-based testing is more sensitive than cytology alone for detecting important precancer, which is why clinician-collected primary hrHPV testing is now preferred. Cytology remains useful, especially as follow-up after a positive HPV result and where HPV-based screening is not available. Evidence syntheses support the shift toward HPV-based screening while also showing why test choice and interval must travel together (Arbyn 2022; Pileggi 2014).

Self-collection changes the experience as well as the specimen. It is a vaginal sample for hrHPV testing, not a cervical-cell sample and not a self-administered Pap test. Depending on the exact FDA labeling, the approved workflow may involve collection in a health setting or another authorized setting. A clinician must order or approve the test, and the program must be able to document the screen, communicate the result, and arrange follow-up. A positive self-collected test may need a clinician-collected cervical sample for cytology or other evaluation before risk can be fully assessed.

The current age-based schedule#

For average-risk patients, the ACOG Committee Statement and HRSA-WPSI recommendation can be summarized this way:

• Ages 21 to 29: cervical cytology alone every 3 years. Co-testing is not recommended before 30 under this framework.
• Ages 30 to 65: clinician-collected primary hrHPV testing every 5 years is preferred. Co-testing every 5 years is acceptable. Cytology alone every 3 years is used when HPV-based options are unavailable or chosen after counseling.
• Ages 30 to 65, patient-collected option: primary hrHPV screening every 3 years may be considered when the patient prefers it, the kit and workflow follow FDA authorization, and result-notification and follow-up systems are in place.

Notice what is missing: anyone under 21. Screening is not recommended before age 21 even for people who are sexually active, and that surprises many people, so the reasoning is worth stating plainly.

In adolescents and people in their late teens and early twenties, HPV is very common and the immune system clears most of these infections on its own within a year or two. Screening this group would mostly find cell changes that were going to resolve anyway. Acting on those findings means procedures, biopsies, and worry, all to treat something that was never going to become cancer. Starting at 21 reflects a deliberate judgment that, in younger people, screening tends to cause harm without a matching benefit.

Why the intervals differ#

A common reaction to a 5-year interval after a clinician-collected HPV screen is unease. The biology and test performance explain why that interval can be appropriate for an average-risk person with a negative result.

The journey from a new high-risk HPV infection to invasive cancer typically takes many years, often a decade or more. Most infections never get anywhere near that far, because they clear. And a negative high-risk HPV test is strongly reassuring: if the virus that drives nearly all cervical cancer is not detectable now, the odds of a dangerous lesion appearing in the next few years are very low. That is what makes a longer interval safe rather than reckless.

Shorter intervals are not free. Screening too often produces more false alarms, colposcopies, biopsies, anxiety, and treatment of low-grade lesions that might regress. But intervals cannot simply be transferred between collection methods. ACOG uses 5 years for clinician-collected primary hrHPV testing and co-testing, 3 years for cytology alone, and 3 years for patient-collected primary hrHPV testing because current self-collection evidence does not yet establish a 5-year interval.

What an abnormal result does and does not mean#

Because these tests are done so widely, abnormal and HPV-positive results are common, and it is worth normalizing that before it happens to you. An abnormal result rarely means cancer. It usually means a transient infection or a minor, low-grade cell change, the kind that often resolves on its own.

What happens next is risk-based, and it depends on the specific result. Common paths include:

• Repeat testing, often in about a year, to see whether a low-grade change or an HPV infection has cleared.
• HPV genotyping, which looks specifically for the highest-risk types such as HPV 16 and 18, since those carry more concern and may prompt a closer look sooner.
• Colposcopy, an office procedure in which a clinician examines the cervix with magnification and can take a small biopsy if something looks worth sampling.

None of these first steps is treatment. They are ways of sorting who genuinely needs attention from the much larger group whose findings will settle down. The most useful thing you can do with an abnormal result is ask what your specific result means and what follow-up interval your clinician recommends.

When screening stops or does not apply#

Screening has endpoints as well as a starting point, and knowing them prevents both under- and over-testing.

Routine screening can generally stop after age 65 for people who are not otherwise at high risk and have adequate prior negative screening. ACOG defines that history as three consecutive negative cytology results or two consecutive negative co-tests within the prior 10 years, with the most recent result within 3 years for cytology alone or 5 years for co-testing. Do not assume eligibility from age alone; the prior record matters.

Routine screening is also not recommended after hysterectomy with removal of the cervix when there is no history of cervical cancer or another high-grade precancerous lesion. And under this framework, routine screening does not begin before age 21.

There are exceptions that run in the other direction. People with certain risk factors, such as a history of high-grade precancer or a weakened immune system, may follow different schedules that are longer in duration or more frequent, and those plans should be set with a clinician rather than read off a general chart.

One more point deserves emphasis: HPV vaccination does not replace screening. The vaccine substantially lowers risk, but it does not cover every high-risk type, and many adults received it after possible contact with the virus. Vaccinated people follow the same screening schedule as everyone else.

Who needs a different plan#

These intervals are for routine screening in people at average risk. They do not cover every situation. A history of cervical cancer or high-grade precancer, HIV, another cause of immune compromise, contact with diethylstilbestrol (DES) before birth, an abnormal current result, or inadequate prior screening can change the test, interval, follow-up, or stopping age. Surveillance after treatment is not the same as routine screening.

The 2026 ACOG statement is a qualified endorsement of the updated HRSA-WPSI framework. Clinically, it identifies clinician-collected primary hrHPV testing as preferred and adds carefully governed patient self-collection. Separately, HRSA states that the updated federal preventive-services coverage guideline becomes effective for most health-plan years beginning in 2027; insurance coverage before then may vary. Clinical eligibility and insurance coverage are related questions, but they are not the same question.

What to take from this#

Three details are worth carrying forward. First, match the interval to the exact strategy: clinician-collected primary hrHPV every 5 years, co-testing every 5 years, cytology every 3 years, or qualified patient-collected primary hrHPV every 3 years for average-risk patients aged 30 to 65. Second, self-collection still requires an authorized kit, clinician involvement, and a reliable follow-up pathway. Third, an abnormal result usually does not mean cancer, but it does require the specific next step recommended for that result. Screening works only when the test, interval, and follow-up stay connected.